Where do we stand in developing radionuclides against molecular markers overexpressed on breast cancer (BC) cells such as EGFR-family members?

Willy Vangu
nuclear medicine, Johannesburg, South Africa
CONTINUE READING

As the BCU 2024 co-president, what's your goal for next edition of the congress end of January 2025?

Willy Vangu
nuclear medicine, Johannesburg, South Africa
CONTINUE READING

What's the prognostic value of PET scan imaging as a predictive tool for ER + breast cancer patients?

Willy Vangu
nuclear medicine, Johannesburg, South Africa
CONTINUE READING

What about the place of radiotherapy after neo adjuvent systemic therapy, can you comment the B51 trial?

Yazid BELKACEMI
radiotherapist, Créteil, France
CONTINUE READING

Can you discuss de-escalation of adjuvant radiotherapy in woman with early breast cancer?

Yazid BELKACEMI
radiotherapist, Créteil, France
CONTINUE READING

What is the benefit of simultaneous integrated boost against sequential boost?

Yazid BELKACEMI
radiotherapist, Créteil, France
CONTINUE READING

How can you predict tumor behavior?

Simon NAYLER
pathologist, Johanesburgh, South Africa
CONTINUE READING

At what stage do you integrate liquid biopsy into breast cancer management? How early?

Simon NAYLER
pathologist, Johanesburgh, South Africa
CONTINUE READING

Copyright © 2026 - BCU